CTOs on the Move

PharmaCord

www.pharmacord.com

 
PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharmacord.com
  • 6100 Dutchmans Lane 12th Floor
    Louisville, KY USA 40205
  • Phone: 502.805.3400

Executives

Name Title Contact Details
Jun Liu
Chief Technology Officer Profile

Similar Companies

Dompé

Dompé: un impegno costante nella ricerca scientifica per lo sviluppo di farmaci innovativi per migliorare lo stato di salute dell’uomo

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BC Technical

BC Technical’s leadership team has over 100 years of combined experience in the medical imaging services market.

PCI Synthesis

PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.